Anti-LAG-3 mAbs or LAG-3 fusion proteins are being tested in melanoma patients resistant to anti-PD-1/PD-L1 ICB as single agent (NCT01968109), or in combination to anti-PD-1 (NCT02676869). Here, CD274 is linked to melanoma.